MX379136B - Proteinas agonistas receptoras cd40 de cadena sencilla. - Google Patents

Proteinas agonistas receptoras cd40 de cadena sencilla.

Info

Publication number
MX379136B
MX379136B MX2017014140A MX2017014140A MX379136B MX 379136 B MX379136 B MX 379136B MX 2017014140 A MX2017014140 A MX 2017014140A MX 2017014140 A MX2017014140 A MX 2017014140A MX 379136 B MX379136 B MX 379136B
Authority
MX
Mexico
Prior art keywords
receptor agonist
agonist proteins
single chain
proteins
cd40l
Prior art date
Application number
MX2017014140A
Other languages
English (en)
Other versions
MX2017014140A (es
Inventor
Christian Gieffers
Meinolf Thiemann
Oliver Hill
Tim Schnyder
Original Assignee
Apogenix Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apogenix Ag filed Critical Apogenix Ag
Publication of MX2017014140A publication Critical patent/MX2017014140A/es
Publication of MX379136B publication Critical patent/MX379136B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153 or CD154

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)

Abstract

La presente invención se refiere a proteínas agonistas receptoras CD40, ácidos nucleicos que codifican para las mismas, y métodos para tratar a un sujeto que presenta una enfermedad o trastorno asociado con CD40L. Las proteínas agonistas receptoras CD40 proporcionadas en la presente comprenden tres dominios solubles CD40L y un fragmento Fc. Las proteínas agonistas receptoras CD40 son sustancialmente no agregantes y adecuadas para aplicaciones terapéuticas, de diagnóstico y/o de investigación.
MX2017014140A 2015-05-04 2016-05-04 Proteinas agonistas receptoras cd40 de cadena sencilla. MX379136B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562156813P 2015-05-04 2015-05-04
PCT/EP2016/059983 WO2016177771A1 (en) 2015-05-04 2016-05-04 Single-chain cd40-receptor agonist proteins

Publications (2)

Publication Number Publication Date
MX2017014140A MX2017014140A (es) 2018-03-15
MX379136B true MX379136B (es) 2025-03-10

Family

ID=56087236

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014140A MX379136B (es) 2015-05-04 2016-05-04 Proteinas agonistas receptoras cd40 de cadena sencilla.

Country Status (12)

Country Link
US (2) US10793616B2 (es)
EP (1) EP3292143B1 (es)
JP (1) JP6738831B2 (es)
KR (1) KR20170138585A (es)
CN (1) CN107709355B (es)
AU (1) AU2016257000B2 (es)
BR (1) BR112017023646A2 (es)
CA (1) CA2984350A1 (es)
ES (1) ES2754432T3 (es)
MX (1) MX379136B (es)
RU (1) RU2745801C2 (es)
WO (1) WO2016177771A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017197231A1 (en) * 2016-05-13 2017-11-16 Medimmune, Llc Cd40l-fc fusion polypeptides and methods of use thereof
AU2017371217B2 (en) 2016-12-09 2020-03-19 Akston Biosciences Corporation Insulin-Fc fusions and methods of use
KR20210005082A (ko) 2018-04-20 2021-01-13 리브젠 바이오파마 코., 엘티디. 항-cd40 항체 및 이의 용도
CN113038964B (zh) 2018-06-29 2025-05-27 德克拉有限公司 超长效胰岛素-fc融合蛋白及使用方法
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
JP7626698B2 (ja) * 2018-09-28 2025-02-04 リビジェン バイオファーマ ホールディングス リミテッド 操作されたＦｃドメインを有する抗ＣＤ４０結合分子およびその治療用途
EP3856790A4 (en) 2018-09-28 2022-09-28 Lyvgen Biopharma Holdings Limited ANTI-CD40 BINDING MOLECULES WITH ENGINEERED FC DOMAINS AND THEIR THERAPEUTIC USES
EP3947454A1 (en) * 2019-03-27 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Recombinant proteins with cd40 activating properties
CN113728008B (zh) 2019-04-10 2024-04-09 南开大学 抗cd40抗体及其用途
CN110760541B (zh) * 2019-10-31 2022-03-29 中国农业科学院兰州兽医研究所 用中国仓鼠卵巢细胞表达外源蛋白时信号肽的选择方法及应用
DK4073098T5 (da) 2019-12-19 2024-07-22 Akston Biosciences Corp Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
US11213581B2 (en) 2020-04-10 2022-01-04 Akston Biosciences Corporation Antigen specific immunotherapy for COVID-19 fusion proteins and methods of use
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
EP4149964A2 (en) 2020-05-15 2023-03-22 Apogenix AG Multi-specific immune modulators
US11667689B2 (en) 2021-07-23 2023-06-06 Akston Biosciences Corporation Insulin-Fc fusion proteins and methods of use to treat cancer
WO2023088876A1 (en) 2021-11-16 2023-05-25 Apogenix Ag Multi-specific immune modulators

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001025277A1 (en) 1999-10-07 2001-04-12 Maxygen Aps Single-chain antagonist polypeptides
DE19963859A1 (de) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
CA2314199A1 (en) 2000-07-21 2002-01-21 Robert Simoneau C-chip
AU2004224123A1 (en) 2003-03-26 2004-10-07 Apogenix Gmbh Treatment of viral infections
DE102004014983A1 (de) 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
UA94213C2 (ru) * 2004-09-17 2011-04-26 Домантис Лимитед Применение полипептида одноцепочечного антитела, который подавляет активность cd40 или cd40l в приготовлении медикамента для лечения аутоиммунного заболевания
EP1871808A2 (en) 2005-03-31 2008-01-02 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES
JP2008537941A (ja) * 2005-03-31 2008-10-02 ゼンコー・インコーポレイテッド 最適化特性を有するＦｃ変異体
WO2009060159A1 (en) * 2007-11-08 2009-05-14 Medigene Limited Mutated ilt molecules
JP2011523853A (ja) 2008-06-03 2011-08-25 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリン及びその使用
US9931386B2 (en) * 2008-06-16 2018-04-03 Atsuo Ochi Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
ES2571879T3 (es) * 2008-07-21 2016-05-27 Apogenix Ag Moléculas de una sola cadena de TNFSF
KR102143887B1 (ko) * 2012-03-16 2020-08-12 유니버시티 헬스 네트워크 Toso 활성을 조절하기 위한 방법 및 조성물
WO2014121099A1 (en) * 2013-01-31 2014-08-07 Thomas Jefferson University Agonist fusion protein for cd40 ox40 and uses thereof
EP3010547B1 (en) * 2013-06-20 2021-04-21 Innate Pharma Enzymatic conjugation of polypeptides
NO2776305T3 (es) * 2014-04-23 2018-01-27

Also Published As

Publication number Publication date
WO2016177771A1 (en) 2016-11-10
CA2984350A1 (en) 2016-11-10
JP6738831B2 (ja) 2020-08-12
WO2016177771A9 (en) 2017-06-29
MX2017014140A (es) 2018-03-15
US20210032309A1 (en) 2021-02-04
CN107709355A (zh) 2018-02-16
US10793616B2 (en) 2020-10-06
US20180066036A1 (en) 2018-03-08
BR112017023646A2 (pt) 2018-07-17
JP2018515072A (ja) 2018-06-14
EP3292143A1 (en) 2018-03-14
AU2016257000B2 (en) 2020-05-14
RU2745801C2 (ru) 2021-04-01
RU2017141727A (ru) 2019-06-04
ES2754432T3 (es) 2020-04-17
RU2017141727A3 (es) 2019-11-05
EP3292143B1 (en) 2019-08-21
KR20170138585A (ko) 2017-12-15
CN107709355B (zh) 2021-09-14
AU2016257000A1 (en) 2017-11-23

Similar Documents

Publication Publication Date Title
MX379136B (es) Proteinas agonistas receptoras cd40 de cadena sencilla.
UA118286C2 (uk) Білок агоніст рецептора trail
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
CY1120390T1 (el) Συνθεση και μεθοδος για διαγνωση και θεραπεια ασθενειων που σχετιζονται με εκφυλισμο νευριτων
CY1121893T1 (el) Μορια αντισωματος κατα της τιμ-3 και χρησεις αυτων
MX2022009625A (es) Receptores de antigenos quimericos condicionalmente activos para celulas t modificadas.
EA201690881A1 (ru) Соединения-ингибиторы аутотаксина
MX2018005720A (es) Anticuerpos pd-l1, fragmento de union al antigeno del mismo, y aplicacion medica de ello.
AR093377A1 (es) Anticuerpos anti-notch y conjugados de anticuerpo-farmaco
MX2017014822A (es) Composiciones y métodos para la reprogramación del tcr con proteínas de fusión.
CR20170181A (es) Compuestos anti-tnf
EP3267884A4 (en) SYSTEMS, DEVICE AND METHOD FOR MEASURING FATTENAL ACTIVITY
EA201791050A1 (ru) Конъюгаты антител и лекарственных средств
EP3294144A4 (en) BONE FRAGMENT AND TISSUE TREATMENT SYSTEM
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
CY1122615T1 (el) Θεραπεια με βλαστοκυτταρα σε παθολογιες τουενδομητριου
EA201790475A1 (ru) Способы лечения системной красной волчанки с использованием доменного антитела против cd28
IL254242A0 (en) Dual signaling fusion proteins and methods of using them to treat diseases
EA201890434A1 (ru) Антитела к cd154 и способы их применения
EP4082450A4 (en) DISSECTION BREAK OCCLUSION SYSTEM
MX2019013124A (es) Proteinas de fusion de inhibidor de tripsina urinaria (uti).
EA201891342A1 (ru) Изоиндольные соединения
CY1122784T1 (el) Αλογονωμενες κιναζολιν-τηf-αμινες ως αναστολεις του ρdε1
MX385925B (es) Oritavancina de alta pureza y método para producir la misma.
EA201890623A1 (ru) Рациональная комбинированная терапия для лечения рака